Axatilimab Shows Efficacy in Recurrent/Refractory GVHD
SAN DIEGO — Axatilimab achieved rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (cGVHD), according to the phase II AGAVE-201 trial. The highest overall response rate (ORR) was observed in patients treated with the lowest dose of axatilimab at 0.3 mg/kg every 2 weeks, with an ORR of 74% (95% CI 63-83) […]
Dramatic, Durable Hair Growth With Oral JAK Inhibitor
BOSTON — An oral Janus kinase (JAK) inhibitor produced significant, durable hair growth, including scalp, eyebrows, and eyelashes in patients with severe alopecia areata, according to long-term data from two randomized trials. Almost 40% of patients achieved a Severity of Alopecia Tool (SALT) score ≤20 (total percentage of hair loss) at 52 weeks with a […]
Another Bioresorbable Stent Hits a Snag
A novel bioresorbable stent failed to meet the threshold for noninferiority compared with durable devices in the OPTIMIZE trial, and researchers suggested rising troponin use may have played a role. The Svelte stent, designed to facilitate direct stenting and transradial access in percutaneous coronary intervention (PCI), did not differ significantly from metallic everolimus-eluting stents with […]